Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

Immunity

Volumn 34, Issue 2, 2011, Pages 269-280

  Bomsel, Morgane ^a,b,c   Tudor, Daniela ^a,b,c   Drillet, Anne Sophie ^a,b,c   Alfsen, Annette ^a,b,c   Ganor, Yonatan ^a,b,c   Roger, Marie Gaëlle ^d   Mouz, Nicolas ^d   Amacker, Mario ^e   Chalifour, Anick ^f   Diomede, Lorenzo ^g   Devillier, Gilles ^h   Cong, Zhe ⁱ   Wei, Qiang ⁱ   Gao, Hong ⁱ   Qin, Chuan ⁱ   Yang, Gui Bo ^j   Zurbriggen, Rinaldo ^e,k   Lopalco, Lucia ^g   Fleury, Sylvain ^f  

^a CNRS   (France)

^b INSTITUT COCHIN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PX'Therapeutics   (France)

^e Pevion Biotech Ltd   (Switzerland)

^f Mymetics Corporation   (Switzerland)

^g Ospedale San Rafaele   (Italy)

^h BD Medical Pharmaceutical Systems   (France)

ⁱ INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^j CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^k LONZA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PLACEBO; VIROSOME; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUCOSAL IMMUNITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SEROCONVERSION; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA MUCOSA; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING SITES; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; IMMUNIZATION; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; TRANSCYTOSIS; VAGINA; VIREMIA; VIROSOMES;

EID: 79951754740     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2011.01.015     Document Type: Article

References (56)

1. Alfsen A., Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 2002, 277:25649-25659.
2. Alfsen A., Iniguez P., Bouguyon E., Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 2001, 166:6257-6265.
3. Amacker M., Engler O., Kammer A.R., Vadrucci S., Oberholzer D., Cerny A., Zurbriggen R. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol. 2005, 17:695-704.
4. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., Ferrai M.G., Weiss D.E., Letvin N.L., Montefiori D., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22:339-348.
5. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 1997, 3:42-47.
6. Bomsel M., Heyman M., Hocini H., Lagaye S., Belec L., Dupont C., Desgranges C. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9:277-287.
7. Bomsel M., Pastori C., Tudor D., Alberti C., Garcia S., Ferrari D., Lazzarin A., Lopalco L. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS 2007, 21:13-22.
8. Bouvet J.P., Fischetti V.A. Diversity of antibody-mediated immunity at the mucosal barrier. Infect. Immun. 1999, 67:2687-2691.
9. Bouvet J.P., Decroix N., Pamonsinlapatham P. Stimulation of local antibody production: Parenteral or mucosal vaccination?. Trends Immunol. 2002, 23:209-213.
10. Brandtzaeg P. Mucosal immunity: Induction, dissemination, and effector functions. Scand. J. Immunol. 2009, 70:505-515.
11. Broliden K., Hinkula J., Devito C., Kiama P., Kimani J., Trabbatoni D., Bwayo J.J., Clerici M., Plummer F., Kaul R. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol. Lett. 2001, 79:29-36.
12. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893. Step Study Protocol Team.
13. Corthésy B. Roundtrip ticket for secretory IgA: Role in mucosal homeostasis?. J. Immunol. 2007, 178:27-32.
14. Coutant J., Yu H., Clément M.J., Alfsen A., Toma F., Curmi P.A., Bomsel M. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J. 2008, 22:4338-4351.
15. Currier J.R., deSouza M., Chanbancherd P., Bernstein W., Birx D.L., Cox J.H. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles. J. Virol. 2002, 76:4971-4986.
16. Delcroix-Genête D., Quan P.L., Roger M.G., Hazan U., Nisole S., Rousseau C. Antiviral properties of two trimeric recombinant gp41 proteins. Retrovirology 2006, 3:16.
17. Demberg T., Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: Strategies and challenges for vaccine design. Int. Rev. Immunol. 2009, 28:20-48.
18. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., Kimani J., Lopalco L., Piconi S., Bwayo J.J., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 2000, 165:5170-5176.
19. Devito C., Hinkula J., Kaul R., Lopalco L., Bwayo J.J., Plummer F., Clerici M., Broliden K. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000, 14:1917-1920.
20. Devito C., Hinkula J., Kaul R., Kimani J., Kiama P., Lopalco L., Barass C., Piconi S., Trabattoni D., Bwayo J.J., et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune Defic. Syndr. 2002, 30:413-420.
21. Donadoni C., Bisighini C., Scotti L., Diomede L., Ngyen M., Nouhin J., DeSantis L., Zambon A., Ferrari D., Gallotta G., et al. Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts. PLoS ONE 2010, 5:e9920.
22. Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009, 4:388-393.
23. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
24. Harouse J.M., Gettie A., Eshetu T., Tan R.C., Bohm R., Blanchard J., Baskin G., Cheng-Mayer C. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 2001, 75:1990-1995.
25. Herzog C., Hartmann K., Künzi V., Kürsteiner O., Mischler R., Lazar H., Glück R. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27:4381-4387.
26. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15:951-954.
27. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., Forthal D.N., Koff W.C., Poignard P., Watkins D.I., Burton D.R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 2010, 84:1302-1313.
28. Hladik F., McElrath M.J. Setting the stage: Host invasion by HIV. Nat. Rev. Immunol. 2008, 8:447-457.
29. Hovanessian A.G., Briand J.P., Said E.A., Svab J., Ferris S., Dali H., Muller S., Desgranges C., Krust B. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity 2004, 21:617-627.
30. Kammer A.R., Amacker M., Rasi S., Westerfeld N., Gremion C., Neuhaus D., Zurbriggen R. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine 2007, 25:7065-7074.
31. Li Y., Yang G.B., Chen Q.M., Liu Q., Meng Z.F., Geng Y.Q., Qiao W.T., Shao Y.M. Construction and characterization of a new simian/human immunodeficiency viruses clone carrying an env gene derived from a CRF07_BC strain. Chin. Med. J. (Engl.) 2009, 122:2874-2879.
32. *2705, bind peptides with sequence similarity. J. Immunol. 2009, 182:7763-7775.
33. Macpherson A.J., McCoy K.D., Johansen F.E., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol. 2008, 1:11-22.
34. Magérus-Chatinet A., Yu H., Garcia S., Ducloux E., Terris B., Bomsel M. Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells. Virology 2007, 362:67-74.
35. Miyazawa M., Lopalco L., Mazzotta F., Lo Caputo S., Veas F., Clerici M. The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 2009, 23:161-175. ESN Study Group.
36. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 2008, 72:54-84.
37. Moser C., Amacker M., Kammer A.R., Rasi S., Westerfeld N., Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev. Vaccines 2007, 6:711-721.
38. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67:6642-6647.
39. Nag P., Kim J., Sapiega V., Landay A.L., Bremer J.W., Mestecky J., Reichelderfer P., Kovacs A., Cohn J., Weiser B., Baum L.L. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect. Dis. 2004, 190:1970-1978.
40. Novitsky V., Cao H., Rybak N., Gilbert P., McLane M.F., Gaolekwe S., Peter T., Thior I., Ndung'u T., Marlink R., et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: Identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J. Virol. 2002, 76:10155-10168.
41. Ogra P.L., Ogra S.S. Local antibody response to poliovaccine in the human female genital tract. J. Immunol. 1973, 110:1307-1311.
42. Pastori C., Clivio A., Diomede L., Consonni R., De Mori G.M., Longhi R., Colombo G., Lopalco L. Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens. J. Virol. 2008, 82:4125-4134.
43. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220. MOPH-TAVEG Investigators.
44. Serres P.F. AIDS: An immune response against the immune system. Role of a precise tridimensional molecular mimicry. J. Autoimmun. 2001, 16:287-291.
45. Shen R., Drelichman E.R., Bimczok D., Ochsenbauer C., Kappes J.C., Cannon J.A., Tudor D., Bomsel M., Smythies L.E., Smith P.D. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J. Immunol. 2010, 184:3648-3655.
46. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001, 17:1757-1765.
47. Sun Z.Y., Oh K.J., Kim M., Yu J., Brusic V., Song L., Qiao Z., Wang J.H., Wagner G., Reinherz E.L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28:52-63.
48. Tatsis N., Lasaro M.O., Lin S.W., Haut L.H., Xiang Z.Q., Zhou D., Dimenna L., Li H., Bian A., Abdulla S., et al. Adenovirus vector-induced immune responses in nonhuman primates: Responses to prime boost regimens. J. Immunol. 2009, 182:6587-6599.
49. Tudor D., Derrien M., Diomede L., Drillet A.S., Houimel M., Moog C., Reynes J.M., Lopalco L., Bomsel M. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: An IgA gene and functional analysis. Mucosal Immunol. 2009, 2:412-426.
50. Vajdy M. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D. 2006, 7:267-288.
51. Vajdy M., Singh M., Kazzaz J., Soenawan E., Ugozzoli M., Zhou F., Srivastava I., Bin Q., Barnett S., Donnelly J., et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 2004, 20:1269-1281.
52. Wilschut J. Influenza vaccS200ines: The virosome concept. Immunol. Lett. 2009, 122:118-121.
53. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
54. Xiao P., Zhao J., Patterson L.J., Brocca-Cofano E., Venzon D., Kozlowski P.A., Hidajat R., Demberg T., Robert-Guroff M. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173.
55. Yu H., Alfsen A., Tudor D., Bomsel M. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent. Cell Calcium 2008, 43:73-82.
56. Zhou F., Goodsell A., Uematsu Y., Vajdy M. Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant. Clin. Vaccine Immunol. 2009, 16:471-478.